Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma.
Paul R BurchardAlexander C ChaconAlexa MelucciAnthony S CasabiancaSubir GoyalJeffrey M SwitchenkoShishir K MaithelDavid A KoobyDarren R CarpizoMihir M ShahPublished in: Journal of surgical oncology (2022)
In resectable PACC, the survival benefit of adjuvant therapy is limited to pathologic stage IIB disease. This benefit is evident even in patients treated with single-agent chemotherapy.